The acquisition includes a mandatory cash tender offer for the remaining shares at €6.25 per share, potentially valuing the entire deal at €300 million and leading to Amplitude's delisting from Euronext Paris.

On March 11, 2025, Zydus Lifesciences announced its intention to acquire an 85.6% stake in Amplitude Surgical, a French MedTech leader, for approximately 256.8 million euros (around USD 280 million).

Zydus plans to finance the acquisition through a combination of debt and internal funds, anticipating revenue growth from the medtech segment within the next 18 to 24 months as new products are commercialized.

Sharvil Patel, Managing Director of Zydus, highlighted that this acquisition is a natural extension into medical technology, presenting various growth opportunities in portfolio, capabilities, and geographic reach.

Amplitude Surgical is recognized for its high-quality lower-limb orthopedic technologies and has experienced significant growth in sales and EBITDA, driven by product development and international expansion.

Zydus is entering a growing orthopedic market, projected to rise from $45 billion in 2024 to $60 billion by 2029, leveraging Amplitude's established presence in hips and knees products.

Zydus Lifesciences reported a 29.62% increase in net profit for Q3 FY25, with revenues rising 16.96% year-on-year, indicating strong financial performance.

The acquisition is expected to enhance Amplitude's distribution capabilities through ongoing product development and a computer-assisted program.

Following the acquisition announcement, Zydus Lifesciences' stock fell by 1.2% to Rs 889, nearing its 52-week low, reflecting market reactions to the deal.

The deal is pending regulatory approvals, including from France’s Ministry of Economy, and is expected to be completed in the first half of 2025.

Zydus Lifesciences is currently trading at a price-to-earnings ratio of nearly 20 times estimated FY 2025 earnings, positioning itself competitively within the pharmaceutical sector.

The acquisition price reflects an 80.6% premium over Amplitude's closing price on March 10, 2025, indicating Zydus's commitment to expanding its presence in the international medical devices market.